Is it now the time to plan for global gender-neutral vaccination?
Menée en Finlande sur la période 2007-2014 à partir d'une modélisation et des données d'un essai randomisé portant sur 11 662 filles et 20 513 garçons, cette étude évalue l'efficacité de la vaccinacion contre le papillomavirus humain (HPV16/18) lorsqu'elle est uniquement appliquée aux filles et lorsqu'elle est mixte
In 2006 the first Human papillomavirus (HPV) vaccines were launched for public use. 14 years later, plans are underway to reduce global incidence of cervical cancer below an incidence of 4 per 100,000, aso-called elimination threshold. Cervical cancer is the most serious and common cancer associated with HPV. It is the fourth most common female malignancy worldwide in both incidence and in mortality, with an estimated 570,000 new cases and 311,000 new deaths in 2018. Ways to control the disease include HPV vaccination and effective cervical cancer screening. The main target population for HPV vaccination is females ages 9 to 14. In this population the efficacy of the vaccine is close to 100% for the vaccine types, and it is predicted to produce major reduction of HPV related disease.
The Journal of Infectious Diseases , commentaire en libre accès, 2019